Reality Check on Chronic Lymphocytic Leukemia
Market access for chronic lymphocytic leukemia (CLL) treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Under the pharmacy benefit, almost 51% of the lives under commercial formularies are covered with utilization management restrictions
- Class Trends: In April 2020, the FDA expanded the label for Pharmacyclics LLC, an AbbVie Inc. company, and Janssen Biotech, Inc.’s Imbruvica (ibrutinib) in combination with rituximab for the treatment of adults newly diagnosed with chronic lymphocytic leukemia or small lymphocytic leukemia
- Key Findings: There have been multiple clinical trials that have proven beneficial results using nonchemotherapy combinations, some of which have been approved by the FDA. There are several targeted drugs currently being evaluated in the pipeline, as well as research in CAR T-cell therapy
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.